Pinned Tweet
How do myelin-specific T cells migrate to the central nervous system during the initial phase of neuroinflammation? Check out our recent publication in @NatureNeuro #MultipleSclerosis #CRISPR #tcell #Transmigration
A genome-wide in vivo #CRISPR screen identifies essential regulators of T cell migration to the CNS in a multiple sclerosis model
New from @kerlab @KawakamiLab @arekken @claradelarosa96 et al.
nature.com/articles/s41593-0…
Arekken retweeted
1/ Most genes and variants matter somewhere but look silent in any one cell model. Can we build conditions that reveal phenotypes? With @kanishkadey, we engineer cell states to expose hidden disease biology and trace how genetic risk reaches disease genes. biorxiv.org/content/10.64898…
Arekken retweeted
The trogocytosis plot of T cell-B cell interactions thickens!
T–B interactions yield CD3+ B cells and CD20+ T cells with pathogenic features in multiple sclerosis
pnas.org/doi/10.1073/pnas.26…
Arekken retweeted
Geleneksel akademik yapılar yaratıcılığı nasıl öldürüyor ve genç araştırmacıları nasıl engelliyor?
Bilimsel yaratıcılığın önündeki en büyük engellerden biri, artık kaynak ya da teknoloji eksikliği değil; akademinin kendi kurduğu teşvik sistemi olabilir.
Nature Human Behaviour’da yayımlanan bu yazı, günümüz akademik yapısının özellikle genç araştırmacıları özgün ve riskli fikirlerden uzaklaştırdığını savunuyor. Kısa fon dönemleri, sürekli yayın baskısı, atıf ve dergi metriklerine dayalı değerlendirmeler ile güvencesiz çalışma koşulları; araştırmacıları sonucu öngörülebilen, hızlı tamamlanabilecek ve kolay yayımlanabilecek projelere yönlendiriyor.
Böyle bir sistemde bilimsel risk almak değil, sisteme stratejik olarak uyum sağlamak ödüllendiriliyor. Sonuçta dönüşüm yaratabilecek çalışmalar yerine, mevcut bilgiyi küçük adımlarla genişleten güvenli araştırmalar çoğalıyor.
Bunun bedelini en fazla kariyerinin başındaki araştırmacılar ödüyor. Henüz bilimsel bağımsızlıklarını kazanmadan hiyerarşik ilişkilere, kısa vadeli sözleşmelere ve sürekli üretkenlik baskısına maruz kalıyorlar. Özgün fikirler geliştirmeleri beklenen dönemde, başarısız olma ihtimali bulunan projelerden kaçınmayı öğreniyorlar.
Yazının bence en önemli mesajı olarak şu söylenebilir "Bilimsel yaratıcılık yalnızca bireysel zekâ veya yetenek değildir; onu mümkün kılan akademik ortamın ortaya çıkardığı bir özelliktir."
Gerçekten dönüştürücü bilim istiyorsak yalnızca “daha yaratıcı araştırmacılar” aramak yetmez. Uzun vadeli ve istikrarlı fonlama, daha bağımsız araştırma ortamları ve yayın sayısı yerine özgünlüğü, iş birliğini, sürekliliği ve bilimsel cesareti değerlendiren bir sistem kurmamız gerekir.
Aksi hâlde bilim insanlarından büyük sorular sormalarını isteyip, kariyerlerini küçük ve risksiz cevaplar vermeye bağlamaya devam edeceğiz.
nature.com/articles/s41562-0…
nature.com/articles/s41562-0…
Arekken retweeted
Incredibly excited to share the first major paper from my lab @carnevale_lab led by postdoc Qi Liu @GladstoneInst @UCSF executing the first ever genome-wide in vivo screens for genetic modifications to enhance human T cell therapies for solid tumors. Now in @Nature: nature.com/articles/s41586-0…
Arekken retweeted
Really provocative new paper from Martin Weber's group on B cell protein trogocytosis by T cells
nature.com/articles/s41467-0…
Arekken retweeted
🔴ODTÜ'lüler rektöre sırtını döndü, ıslıklarla protesto etti
📢Türkiye Komünist Gençliği: ODTÜ, AKP'nin memuruna karşı bütün kuvvetiyle, geleceğine ve iradesine sahip çıkmak için haykırıyor!
haber.sol.org.tr/haber/odtul…
Nature research paper: Dual tumour–myeloid targeting of glioblastoma with GPNMB CAR-T cells
go.nature.com/3QCD910
Arekken retweeted
Latent, Lytic, and Linked to Multiple Sclerosis—How EBV Drives Autoimmunity
onlinelibrary.wiley.com/doi/…
CAR-T cell therapy seems to have reset the immune system and eased severe symptoms in eight children and adolescents with autoimmune disorders
go.nature.com/4qNUYGq
Arekken retweeted
Excited to share VIPerturb-seq!
New tech from my lab which aims to improve the cost, data quality, and efficiency of single-cell CRISPR screens so that they are accessible to any lab - even at genome-wide scale
Preprint and 🧵 (1/): biorxiv.org/content/10.64898…
Arekken retweeted
Phase 2 Relapsing #MS MoonStone 12-week results: 95% reduction in contrast-enhancing lesions compared to placebo.
#Obexelimab is a humanized monoclonal antibody that inhibits CD19 and FcyRllb
without inducing cytotoxicity.
@ACTRIMS #ACTRIMSForum
Arekken retweeted
Overjoyed to share our new work exploring the antigen specificity of CSF-expanded CD8+ T cells in #multiplesclerosis #EBV in @natimmunol 🧵1/
nature.com/articles/s41590-0…
Arekken retweeted
TimeVault transforms vault particles into transcriptome recording devices, which are applied to uncover transcriptional heterogeneity in drug-tolerant persister cancer cells #NBThighlight science.org/doi/10.1126/scie…
Arekken retweeted
EBV is required for the development of multiple sclerosis, but it’s not known how a common virus leads to disease. 3 exciting new papers in @CellCellPress provide major insights into how this may occur:
New insight into the immune signals driving inflammation in multiple sclerosis medicalxpress.com/news/2026-… via @medical_xpress - @NatureNeuro
1
48
Arekken retweeted
The immune system is powerful.
Sometimes, too powerful.
If it goes unchecked, it can turn on us -
attacking our own organs, tissues, even our blood.
That’s why the 2025 Nobel Prize in Medicine matters so much.
It honors three scientists who figured out how the body stops itself from self-destructing.
🧬 Mary Brunkow
🧪 Fred Ramsdell
🧫 Shimon Sakaguchi
Here’s the story :👇
Every day, your body fights off thousands of invaders - viruses, bacteria, fungi.
But the real magic? It knows not to attack you.
That precision is everything.
And for decades, scientists thought they knew how it worked:
Bad immune cells were weeded out early in the thymus (central tolerance). End of story.
Except… that wasn’t the whole story.
Sakaguchi’s bold idea (1995)
He challenged the dogma.
He found a new class of immune cells doing something unexpected:
➡️ They weren’t attacking.
➡️ They were protecting.
He called them regulatory T cells - the immune system’s peacekeepers.
They roam the body and tell other immune cells:
“Stand down. This is us. Don’t attack.”
It was a radical idea at the time. But he was right.
Brunkow & Ramsdell’s breakthrough (2001)
They were studying a mysterious mouse.
It had a single mutation - and developed devastating autoimmune disease.
They found the cause: a gene called Foxp3.
🧬 Foxp3 isn’t just any gene.
It’s the master switch that tells cells to become regulatory T cells - the same ones Sakaguchi discovered.
Mutate it in mice or humans… and the immune system spins out of control.
In kids, that mutation causes a rare and deadly disease: IPEX syndrome.
The missing link (2003)
Sakaguchi came back to close the loop.
He proved that Foxp3 is what powers the regulatory T cells - the body’s tolerance enforcers.
This confirmed the whole mechanism.
➡️ We don’t just delete dangerous immune cells early on.
➡️ We also deploy specialized cells to watch over the rest.
➡️ That’s how we avoid autoimmune chaos.
The impact? Massive.
Their discoveries opened an entire new field: peripheral immune tolerance.
We now have:
🔹 New approaches to treat autoimmune diseases
🔹 Promising advances in organ transplant tolerance
🔹 Immunotherapies that fine-tune the immune system to fight cancer - without turning on the body
Some of these are already in clinical trials.
This isn’t just a scientific triumph.
It’s a reminder that:
✅ Curiosity still drives paradigm shifts.
✅ Going against the mainstream can change everything.
✅ Basic science leads to better medicine.
And sometimes, three scientists working decades apart can quietly solve one of biology’s deepest mysteries.
👉 That’s worth a Nobel.
Arekken retweeted
Finite-course ocrelizumab in relapsing multiple sclerosis: Results of two prospective open-label trials with matched controls
journals.sagepub.com/doi/10.…
Arekken retweeted
🛡️How do macrophages tailor their defenses to different pathogens? Our new paper in @CellSystems combines dense multi-omics time series with high‐content CRISPR screens (CROP-seq) to map the regulatory landscape underlying macrophage immune responses. #Immunity #Screening (1/9)
Arekken retweeted
A cost-effective ultra-high-throughput cytometry-based framework for the detection of physical interactions between cells, along with the characterization of complex cellular landscapes @naturemethods
nature.com/articles/s41592-0…
nature.com/articles/s41592-0…
Arekken retweeted
Symptomatic primary EBV infection generates B cell subsets that gain access to the CNS, attract T cells and thereby initiate multiple sclerosis @Nature
nature.com/articles/s41586-0…






















